Keywords
Neoplasms
Gastrointestinal Cancer
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze the prevalence of cancer with the prologated use of Proton Pump Inhibitors (PPIs). Methods: Integrative Literature Review study of exploratory nature emerging from the problematic "What is the prevalence and risks of cancer with prolonged use of Proton Pump Inhibitor drugs?" in the Scientific Electronic Library Online (SciELO), U.S. National Library of Medicine (PubMed), Medical Literature Analysis and Retrievel System Online (MEDLINE) and Embase databases, between 2011-2021. Results: Based on the quali-quantitative analysis of the 28 studies included in the review, 78.6% exposed a positive relationship to prolonged use of PPIs and prevalence of cancer, with positivity for gastric (86.7%), pancreas (80%), hepatic (75%), gastrointestinal (66.7%), esophagus, biliary tract (50%) and colorectal tract (44.4%). Final considerations: There is a literary divergence regarding the prolonged use of PPIs and neoplasms, however, the results are more frequent for studies addressing a significant positive association with prolonged use and gastric, colorectal, esophagus, pancreas, hepatic and gastrointestinal cancer. However, although its benefits well described in the literature, the present study presents sufficient evidence to recommend the rational use of PPIs considering criteria and monitoring of individuals submitted to treatments with such drugs.
References
ABRAHAMI D, et al. Proton pump inhibitors and risk of gastric cancer: population-based cohort study. Gut, 2022; 71: 16-24.
AHN JS, et al. Use of Proton Pump Inhibitor and Risk of Colorectal Cancer: A Meta-analysis of Observational Studies. Korean J Fam Med. 2012; 33(5): 272-9.
AHN JS, et al. Acid suppressive drugs and gastric cancer: a meta-analysis of observational studies. World J Gastroenterol, 2013; 19(16): 2560-2568.
BRUSSELAERS N, et al. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017; 7(10).
BRUSSELAERS N, et al. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol, 2018; 53: 172-177.
BRUSSELAERS N, et al. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. Journal of Gastroenterology, 2019; 55(4).
CAMILO SMP, et al. Uso crônico de inibidores de bomba de prótons e a quantidade de células G, D e ECL no estômago. ABCD Arq Bras Cir Dig, 2020; 33(2): e1506.
CHEUNG KS e LEUNG WK. Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Therap Adv Gastroenterol. 2019; 11(12).
DALL’OLMO L, et al. Role of Proton Pump Inhibitor on Esophageal Carcinogenesis and Pancreatic Acinar Cell Metaplasia Development: An Experimental In Vivo Study. PLoS ONE, 2014; 9(11).
DUY AT, et al. Use of Proton Pump Inhibitors and Risks of Fundic Gland Polyps and Gastric Cancer: Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2016; 14: 1706-1719.
FINCK EM e SUGAWARA AM. Associação do uso dos inibidores de bomba de Prótons ao Câncer Gástrico. Revista Científica Multidisciplinar Núcleo do Conhecimento, 2021; 6(5): 26-39.
HWANG IC, et al. Emerging hazard effects of proton pump inhibitor on the risk of colorectal cancer in low-risk populations: A Korean nationwide prospective cohort study. PLoS One, 2017; 12(12).
KAMAL H, et al. Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study. Hepatology, 2021; 74(4): 2021-2031.
KEARNS MD, et al. Proton pump inhibitors on pancreatic cancer risk and survival. Cancer Epidemiol, 2017; 46: 80.
KROUPA R, et al. Incidence trends of esophageal cancer in the Czech Republic by histological subtype and stage and prescription rate of acid suppressing drugs. Cancer Epidemiol, 2020; 69: 101853.
KUIPER JG et al. Proton pump inhibitors are not associated with an increased risk of colorectal cancer. GastroHep, 2020; 165-170.
LEI WY, et al. Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study. Clin Res Hepatol Gastroenterol, 2021; 45(1).
LIU R e SHAO Y. The use of a proton pump inhibitor does not increase the risk of colorectal cancer: a meta-analysis. J Gastrointestin Liver Dis, 2020; 29(4).
LIU P, et al. Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies. Br J Cancer. 2020; 123(2): 307-315.
MCGWIN, G. The Associa tion between Ranitidine Use and Gas trointestinal Cancers. Cancers, 2021; 1.
MELO IO, et al. Inibidores da bomba de prótons e carcinogênese: uma revisão da literatura / Proton pump inhibitors and carcinogenesis: a literature review. Rev Med., 2021; 100(5): 479-85.
MOAYYEDI P, et al. Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology 2019; 157: 682-691.
MOGHADDAM EM, et al. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions? Arch Iran Med, 2013; 1.
ORGANIZAÇÃO MUNDIAL DA SAÚDE – OMS. (2020). Folha informativa atualizada em outubro de 2020; 10.
PAIVA AA, et al. Possível relação entre o uso de inibidores de bomba de prótons e neoplasias. Research, Society and Development, 2021; 10(5).
PATEL A, et al. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol, 2021; 27(44): 7716-7733.
SANTOS FAC, et al. Mortalidade por Câncer de Fígado e Vias Biliares no Brasil: Tendências e Projeções até 2030. Revista Brasileira de Cancerologia, 2019; 65(4).
SCHNEIDER JL, et al. Risk of gastric cancer, gastrointestinal cancers and other cancers: a comparison of treatment with pantoprazole and other proton pump inhibitors. Aliment Pharmacol Ther, 2016; 43(1): 73-82.
SEGNA D, e al. Association between proton-pump inhibitors and the risk of gastric cancer: a systematic review with meta-analysis. Therapeutic Advances in Gastroenterology, 2021; 22.
SILVA WCF, et al. Perfil Clínico-Epidemiológico e Sobrevida Global em Pacientes com Adenocarcinoma de Pâncreas em um Hospital de Referência em Oncologia. Revista Brasileira de Cancerologia, 2021; 67(1).
SOUZA MT, et al. Revisão integrativa: o que é e como fazer. Einstein. 2010; 1.
SONG H, et al. Long-term proton pump inhibitor (PPI) use and the development of gastric pre-malignant lesions. Cochrane Database Syst Rev, 2014; 2: 12.
SONG HJ, et al. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. Eur J Clin Pharmacol, 2020; 76(6): 851-866.
SOUZA IKF, et al. Análise qualitativa das alterações anatomopatológicas na mucosa gástrica decorrentes da terapêutica prolongada com inibidores da bomba de prótons: estudos experimentais x estudos clínicos. ABCD Arq Bras Cir Dig, 2013; 26(4): 328-334.
WALDUM HL, et al. Proton pump inhibitors (PPIs) may cause gastric cancer–clinical consequences. Scand J Gastroenterol, 2019; 53(6).
ZENG R, et al. Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers, European Journal of Cancer, 2021; 156(24): 190-201.